These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Lemstrova R; Melichar B; Mohelnikova-Duchonova B Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969 [TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy for pancreatic cancer: an evolving paradigm. Zhu AX; Clark JW; Willett CG Surg Oncol Clin N Am; 2004 Oct; 13(4):605-20, viii. PubMed ID: 15350937 [TBL] [Abstract][Full Text] [Related]
24. Chemoradiotherapy for pancreatic cancer: current status and perspectives. Oya N Int J Clin Oncol; 2004 Dec; 9(6):451-7. PubMed ID: 15616875 [TBL] [Abstract][Full Text] [Related]
25. Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Marsh Rde W; George T Curr Gastroenterol Rep; 2006 Apr; 8(2):111-20. PubMed ID: 16533473 [TBL] [Abstract][Full Text] [Related]
26. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022 [TBL] [Abstract][Full Text] [Related]
27. [Clinical study of the month. Adjuvant radio-chemotherapy and chemotherapy following curative resection of pancreatic cancer: results of the randomized trial ESPAC-1]. Polus M; Jerusalem G; Sautois B; Silvestre RM; Collette MY; Closon MT; Fillet G Rev Med Liege; 2002 Feb; 57(2):119-22. PubMed ID: 11942178 [TBL] [Abstract][Full Text] [Related]
28. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Valeri S; Borzomati D; Nappo G; Perrone G; Santini D; Coppola R Pancreatology; 2014; 14(5):425-30. PubMed ID: 25278312 [TBL] [Abstract][Full Text] [Related]
29. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. Al Haddad AH; Adrian TE Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674 [TBL] [Abstract][Full Text] [Related]
30. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies. Matera R; Saif MW Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977 [TBL] [Abstract][Full Text] [Related]
31. Treatment for pancreatic cancer: current therapy and continued progress. Lockhart AC; Rothenberg ML; Berlin JD Gastroenterology; 2005 May; 128(6):1642-54. PubMed ID: 15887156 [TBL] [Abstract][Full Text] [Related]
32. Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy. Colloca GA; Venturino A; Guarneri D Clin Exp Metastasis; 2019 Dec; 36(6):519-525. PubMed ID: 31578654 [TBL] [Abstract][Full Text] [Related]
33. Promising new therapies in advanced pancreatic adenocarcinomas. Kundranda M; Kachaamy T Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049 [TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229 [TBL] [Abstract][Full Text] [Related]
36. Treatment of locally advanced pancreatic cancer: the role of radiation therapy. Johung K; Saif MW; Chang BW Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):508-18. PubMed ID: 22075449 [TBL] [Abstract][Full Text] [Related]
37. Preclinical Rationale for the Phase III Trials in Metastatic Pancreatic Cancer: Is Wishful Thinking Clouding Successful Drug Development for Pancreatic Cancer? Thota R; Maitra A; Berlin JD Pancreas; 2017 Feb; 46(2):143-150. PubMed ID: 28085753 [TBL] [Abstract][Full Text] [Related]
38. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
39. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]